Literature DB >> 29554473

A Molecular Subtype-Specific Stochastic Simulation Model of US Breast Cancer Incidence, Survival, and Mortality Trends from 1975 to 2010.

Diego F Munoz1, Cong Xu1, Sylvia K Plevritis1.   

Abstract

We present a Monte Carlo simulation model that reproduces US invasive breast cancer incidence and mortality trends from 1975 to 2010 as a function of screening and adjuvant treatment. This model was developed for multiple purposes, including to quantify the impact of screening and adjuvant therapy on past and current trends, predict future trends, and evaluate potential outcomes under hypothetical screening and treatment interventions. The model first generates the life histories of individual breast cancer patients by determining the patient's age, tumor size, estrogen receptor (ER) status, human epidermal growth factor 2 (HER2) status, SEER (Surveillance, Epidemiology, and End Results) historic stage, detection mode at time of detection, preclinical tumor course, and death age and cause of death (breast cancer v. other causes). The model incorporates common inputs used by the Cancer Intervention and Surveillance Modeling Network (CISNET), including the dissemination patterns for screening mammography, breast cancer survival in the absence of adjuvant therapy, dissemination and efficacy of treatment by ER and HER2 status, and death from causes other than breast cancer. In this article, predicted mortality outcomes are compared assuming proportional v. nonproportional hazards effects of treatment on breast cancer survival. We found that the proportional hazards treatment effects are sufficient for ER-negative disease. However, for ER-positive disease, the treatment effects appear to be higher during the early years following diagnosis and then diminish over time. Using nonproportional hazards effects for ER-positive cases, the predicted breast cancer mortality rates closely match the SEER mortality trends from 1975 to 2010, particularly after 1995. Our work indicates that population-level simulation modeling may have a broader role in assessing the time dependence of treatment effects.

Entities:  

Keywords:  SEER; breast cancer incidence trends; breast cancer mortality trends; nonproportional hazards; time-dependent treatment effects

Mesh:

Substances:

Year:  2018        PMID: 29554473      PMCID: PMC6538507          DOI: 10.1177/0272989X17737508

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  5 in total

1.  Association of Screening and Treatment With Breast Cancer Mortality by Molecular Subtype in US Women, 2000-2012.

Authors:  Sylvia K Plevritis; Diego Munoz; Allison W Kurian; Natasha K Stout; Oguzhan Alagoz; Aimee M Near; Sandra J Lee; Jeroen J van den Broek; Xuelin Huang; Clyde B Schechter; Brian L Sprague; Juhee Song; Harry J de Koning; Amy Trentham-Dietz; Nicolien T van Ravesteyn; Ronald Gangnon; Young Chandler; Yisheng Li; Cong Xu; Mehmet Ali Ergun; Hui Huang; Donald A Berry; Jeanne S Mandelblatt
Journal:  JAMA       Date:  2018-01-09       Impact factor: 56.272

2.  Comparing CISNET Breast Cancer Incidence and Mortality Predictions to Observed Clinical Trial Results of Mammography Screening from Ages 40 to 49.

Authors:  Jeroen J van den Broek; Nicolien T van Ravesteyn; Jeanne S Mandelblatt; Hui Huang; Mehmet Ali Ergun; Elizabeth S Burnside; Cong Xu; Yisheng Li; Oguzhan Alagoz; Sandra J Lee; Natasha K Stout; Juhee Song; Amy Trentham-Dietz; Sylvia K Plevritis; Sue M Moss; Harry J de Koning
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

3.  Introduction to the Cancer Intervention and Surveillance Modeling Network (CISNET) Breast Cancer Models.

Authors:  Oguzhan Alagoz; Donald A Berry; Harry J de Koning; Eric J Feuer; Sandra J Lee; Sylvia K Plevritis; Clyde B Schechter; Natasha K Stout; Amy Trentham-Dietz; Jeanne S Mandelblatt
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

4.  Comparing CISNET Breast Cancer Models Using the Maximum Clinical Incidence Reduction Methodology.

Authors:  Jeroen J van den Broek; Nicolien T van Ravesteyn; Jeanne S Mandelblatt; Mucahit Cevik; Clyde B Schechter; Sandra J Lee; Hui Huang; Yisheng Li; Diego F Munoz; Sylvia K Plevritis; Harry J de Koning; Natasha K Stout; Marjolein van Ballegooijen
Journal:  Med Decis Making       Date:  2018-04       Impact factor: 2.583

Review 5.  Reflecting on 20 years of breast cancer modeling in CISNET: Recommendations for future cancer systems modeling efforts.

Authors:  Amy Trentham-Dietz; Oguzhan Alagoz; Christina Chapman; Xuelin Huang; Jinani Jayasekera; Nicolien T van Ravesteyn; Sandra J Lee; Clyde B Schechter; Jennifer M Yeh; Sylvia K Plevritis; Jeanne S Mandelblatt
Journal:  PLoS Comput Biol       Date:  2021-06-17       Impact factor: 4.475

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.